Genetic risk factors for venous thromboembolism
Related Experiment Video
Updated: Dec 13, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
Bengt Zöller1, Peter J Svensson2, Björn Dahlbäck3
1Center for Primary Health Care Research, Lund University , Malmö, Sweden.
Insights
Venous thromboembolism (VTE) is a genetic and acquired condition. Identifying genetic risk factors is crucial for managing high-risk individuals and may change future VTE treatment strategies.
Area of Science:
- Genetics
- Thrombosis
- Vascular Medicine
Background:
- Venous thromboembolism (VTE) is a complex familial disease.
- Both acquired and genetic factors contribute to VTE risk.
- Recognizing and managing high-risk individuals is critical.
Purpose of the Study:
- To summarize genetic risk factors for VTE.
- To discuss clinical consequences and future perspectives.
- To explore the impact of genetic variants on VTE management.
Main Methods:
- Review of classical thrombophilia (Factor V Leiden, Prothrombin G20210A, deficiencies of antithrombin, protein C, S).
- Inclusion of findings from Genome-Wide Association Studies (GWAS), Transcriptome-Wide Association Studies (TWAS), and Genetic Risk Scores (GRS).
- Discussion of VTE candidate genes, expression studies, animal models, next-generation sequencing, and pathway analysis.
Main Results:
- Classical thrombophilia variants and deficiencies are established genetic risk factors.
- GWAS, TWAS, and GRS are identifying new genetic contributors to VTE.
- Multiple genetic risk variants are increasingly recognized.
Conclusions:
- Screening for inherited thrombophilia is indicated in specific cases.
- Identification of strong genetic risk variants can influence VTE management.
- The growing number of identified genetic risk variants is expected to transform VTE treatment approaches.
Introduction:
Venous thromboembolism (VTE) is a complex disease that aggregates in families. Both acquired and genetic risk factors are important. Proper recognition and management of high-risk individuals are important.
Areas Covered:
The genetic risk factors for VTE, the clinical consequences, and future perspectives are summarized. Classical thrombophilia i.e., factor V Leiden (rs6025), the prothrombin G20210A mutation (rs1799963), deficiencies of antithrombin, protein C, and protein S and the recent findings from genome wide association studies (GWAS), transcriptome-wide association studies (TWAS), genetic risk score (GRS), VTE candidate genes, expression studies, animal studies, studies using next generation sequencing, pathway analysis, and clinical implications are discussed.
Expert Opinion:
Screening of inherited thrombophilia should be performed in special cases. Identification of strong risk variants might affect the management. The increasing number of genetic risk variants is likely to change management of VTE.
Related Concept Videos
Venous Thrombosis I: Introduction
Varicose Veins I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Cancer Prevention
Some...

